Jaguar Health, Inc.JAGXEarnings & Financial Report
Jaguar Health, Inc. is a commercial-stage biopharmaceutical firm developing and selling plant-derived prescription medicines for humans and animals. Its products target unmet gastrointestinal treatment needs, with main markets in North America and select European regions, covering human health and animal health segments.
JAGX Q4 FY2025 Key Financial Metrics
Revenue
$3.2M
Gross Profit
$1.0M
Operating Profit
$-21.2M
Net Profit
$-23.2M
Gross Margin
32.0%
Operating Margin
-656.6%
Net Margin
-717.2%
YoY Growth
-7.8%
EPS
$10.27
Jaguar Health, Inc. Q4 FY2025 Financial Summary
Jaguar Health, Inc. reported revenue of $3.2M (down 7.8% YoY) for Q4 FY2025, with a net profit of $-23.2M (down 133.9% YoY) (-717.2% margin). Cost of goods sold was $2.2M, operating expenses totaled $22.3M.
Key Financial Metrics
| Total Revenue | $3.2M |
|---|---|
| Net Profit | $-23.2M |
| Gross Margin | 32.0% |
| Operating Margin | -656.6% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
Jaguar Health, Inc. Q4 FY2025 revenue of $3.2M breaks down across 2 segments, led by Human Health Segment at $3.2M (97.4% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Human Health Segment | $3.2M | 97.4% |
| Other | $83.0K | 2.6% |
Jaguar Health, Inc. Revenue by Segment — Quarterly Trend
Jaguar Health, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Human Health Segment and Other) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Human Health Segment | $3.2M | $3.0M | $2.9M | $2.1M |
| Other | $83.0K | $78.0K | $116.0K | $76.0K |
Jaguar Health, Inc. Annual Revenue by Year
Jaguar Health, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $11.5M).
Jaguar Health, Inc. Quarterly Revenue & Net Profit History
Jaguar Health, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $3.2M | -7.8% | $-23.2M | -717.2% |
| Q3 FY2025 | $3.1M | -0.8% | $-9.5M | -308.2% |
| Q2 FY2025 | $3.0M | +9.5% | $-10.4M | -349.3% |
| Q1 FY2025 | $2.2M | -5.8% | $-10.5M | -472.6% |
| Q4 FY2024 | $3.5M | — | $-9.9M | -282.7% |
| Q3 FY2024 | $3.1M | +10.5% | $-9.9M | -317.1% |
| Q2 FY2024 | $2.7M | — | $-9.5M | -348.8% |
| Q1 FY2024 | $2.4M | — | $-9.2M | -392.4% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.4M | $2.7M | $3.1M | $3.5M | $2.2M | $3.0M | $3.1M | $3.2M |
| YoY Growth | N/A | N/A | 10.5% | N/A | -5.8% | 9.5% | -0.8% | -7.8% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $55.4M | $61.5M | $58.5M | $53.4M | $51.5M | $48.3M | $49.5M | $38.3M |
| Liabilities | $41.1M | $42.4M | $42.9M | $44.4M | $48.1M | $41.4M | $45.1M | $57.0M |
| Equity | $11.8M | $16.6M | $13.1M | $6.5M | $830000 | $6.9M | $4.4M | $-18.7M |
Cash Flow
| Q1 2024 | Q4 2024 | Q1 2025 | Q4 2025 | |
|---|---|---|---|---|
| Operating CF | $-7.0M | $-7.8M | $-7.3M | $-5.5M |